Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 7
2004 7
2005 9
2006 6
2007 4
2008 7
2009 6
2010 14
2011 22
2012 21
2013 24
2014 15
2015 25
2016 20
2017 15
2018 9
2019 13
2020 12
2021 16
2022 13
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: lee jh. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: lee jh. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.
Lee KH, Yoon SR, Gong JR, Choi EJ, Kim HS, Park CJ, Yun SC, Park SY, Jung SJ, Kim H, Lee SY, Jung H, Byun JE, Kim M, Kim SY, Kim JH, Lee JH, Lee JH, Choi Y, Park HS, Lee YS, Kang YA, Jeon M, Woo J, Kang H, Baek S, Kim SM, Kim HM, Cho KH, Choi I. Lee KH, et al. Among authors: lee jh. Leukemia. 2023 Apr;37(4):807-819. doi: 10.1038/s41375-023-01849-5. Epub 2023 Mar 17. Leukemia. 2023. PMID: 36932165 Clinical Trial.
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study.
Baek DW, Park HS, Sohn SK, Kim DY, Kim I, Ahn JS, Do YR, Lee SR, Eom HS, Lee WS, Kim SH, Lee HS, Lee YJ, Moon JH, Lee JH; Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology. Baek DW, et al. Among authors: lee jh. Korean J Intern Med. 2023 Sep;38(5):734-746. doi: 10.3904/kjim.2022.401. Epub 2023 Jun 20. Korean J Intern Med. 2023. PMID: 37334511 Free PMC article. Clinical Trial.
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Perl AE, et al. Among authors: lee jh. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. Blood Cancer J. 2022. PMID: 35637252 Free PMC article.
Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS, Jang JH, Jo DY, Ahn SY, Yoon SS, Lee JH, Kim SH, Choi CW, Shin HJ, Kim MK, Lee JH, Mun YC, Kong JH, Hyun B, Nam H, Kim E, Kwak MJ, Won YK, Lee JW. Kim JS, et al. Among authors: lee jh. J Korean Med Sci. 2023 Oct 23;38(41):e328. doi: 10.3346/jkms.2023.38.e328. J Korean Med Sci. 2023. PMID: 37873628 Free PMC article.
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy.
Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, Gimenez Conca A, Castillo TBD, Girshova L, Martelli MP, Guvenc B, Delgado A, Duan Y, Garbayo Guijarro B, Llamas C, Lee JH. Miyamoto T, et al. Among authors: lee jh. Leuk Lymphoma. 2022 Apr;63(4):928-938. doi: 10.1080/10428194.2021.2002321. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147482
234 results